PD-1/CTLA-4 dual-function antibody
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PD-1/CTLA-4 dual-function antibody, covering 2025-12-29 to 2025-12-29. Get the full timeline:
Most recent: Clinical Trial Update: IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy [Phase 2]